DaVita shares fell after the company's 2025 earnings missed expectations and Berkshire Hathaway sold shares in the company. The stock declined 10% to $158.96 on Friday, though it is up about 30% over ...

DaVita Inc.'s stock was tumbling 13.5% Friday to lead S&P 500 decliners, after Warren Buffett's Berkshire Hathaway Inc. pared its stake in the provider of kidney dialysis.

In a major milestone for the company, DaVita recently celebrated its 25th anniversary of delivering exceptional kidney care ...

In terms of intangible assets, DaVita has built the largest network of dialysis clinics in the US over several decades, based in part on its brand and reputation for high-quality services, extensive ...

DaVita shares tumbled after issuing a weak outlook amid rising care costs, while big investor Berkshire offloaded some shares ...

Truist Financial analyst David S Macdonald maintained a Hold rating on DaVita (DVA – Research Report) today. The company’s shares closed ...

In a report released today, Ryan Langston from TD Cowen maintained a Hold rating on DaVita (DVA – Research Report), with a price target of ...

The increasing prevalence of kidney failure and end-stage renal disease, along with a growing incidence of risk factors like diabetes, hypertension, and aging, is driving the demand for artificial ...

DelveInsight's Artificial Kidney Market Insights report provides the current and forecast market analysis, individual leading ...

DaVita Inc. closed 1.41% short of its 52-week high of $179.60, which the company reached on January 31st.